Company intelligence / Profile preview

Incendia Therapeutics

Cambridge, Massachusetts, United Statesincendiatx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Incendia’s lead asset PRTH‑101 is a first-in-class monoclonal antibody targeting DDR1. It is currently being evaluated in a Phase 1c clinical trial as monotherapy and in combination with PD‑1 inhibition for patients with immune checkpoint inhibitor-refractory thymic carcinoma. Early data presented at ESMO show high DDR1 expression across multiple tumor types and support the rationale for targeting DDR1 to improve immune cell infiltration into tumors. No approved drugs currently target DDR1. The company plans to initiate pivotal Phase 2 trials soon.[4]

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies[1][2]Novel anti-cancer biologics[4]
Industry: Biotech

Drug pipeline

2 assets

PRTH-101

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Incendia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Incendia Therapeutics.

Explore the full profile